Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Nelotanserin

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Nelotanserin
Clinical data
Other namesAPD-125
Routes of
administration		Oral
ATC code
  • none
Identifiers
  • 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea
CAS Number
PubChemCID
ChemSpider
UNII
KEGG
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC18H15BrF2N4O2
Molar mass437.245 g·mol−1
3D model (JSmol)
  • Brc1cnn(C)c1-c2cc(ccc2OC)NC(=O)Nc3ccc(F)cc3F
  • InChI=1S/C18H15BrF2N4O2/c1-25-17(13(19)9-22-25)12-8-11(4-6-16(12)27-2)23-18(26)24-15-5-3-10(20)7-14(15)21/h3-9H,1-2H3,(H2,23,24,26) ☒N
  • Key:COSPVUFTLGQDQL-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Nelotanserin (former developmental code nameAPD-125) is adrug developed byArena Pharmaceuticals which acts as aninverse agonist on theserotonin receptor subtype5-HT2A and was under development for the treatment ofinsomnia.[1] It was shown to be effective and well tolerated in clinical trials,[2][3] but development was halted in December 2008 because the substance did not meet the trial's effectiveness endpoints.[4] Research continues on newer analogues which may potentially be more successful.[5]

Usages

[edit]

Later, nelotanserin wasrepurposed for the treatment ofLewy body dementia (LBD) byAxovant Sciences (now Sio Gene Therapies).[6] In late 2018, the company announced that while nelotanserin was generally well-tolerated by LBD patients in a smallPhase 2 clinical trial for the treatment ofREM sleep behavior disorder (RBD) and there were positive indications on some secondary trial outcomes such as sleep diaries and somepolysomnogram sleep parameters, the drug failed to meet itsprimary endpoint of reducing the frequency of RBD episodes and would be discontinued.[7]

References

[edit]
  1. ^Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD, et al. (March 2010). "Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia".Journal of Medicinal Chemistry.53 (5):1923–36.doi:10.1021/jm9007328.PMID 20143782.
  2. ^Rosenberg R, Seiden DJ, Hull SG, Erman M, Schwartz H, Anderson C, et al. (December 2008)."APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia".Sleep.31 (12):1663–71.doi:10.1093/sleep/31.12.1663.PMC 2603489.PMID 19090322.
  3. ^Al-Shamma HA, Anderson C, Chuang E, Luthringer R, Grottick AJ, Hauser E, et al. (January 2010). "Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia".The Journal of Pharmacology and Experimental Therapeutics.332 (1):281–90.doi:10.1124/jpet.109.160994.PMID 19841476.S2CID 2759858.
  4. ^"APD125 for Insomnia". Arena Pharmaceuticals, Inc. Archived fromthe original on 2009-08-26.
  5. ^Xiong Y, Ullman B, Choi JS, Cherrier M, Strah-Pleynet S, Decaire M, et al. (August 2010). "Synthesis and in vivo evaluation of phenethylpiperazine amides: selective 5-hydroxytryptamine(2A) receptor antagonists for the treatment of insomnia".Journal of Medicinal Chemistry.53 (15):5696–706.doi:10.1021/jm100479q.PMID 20684606.
  6. ^"Nelotanserin - Axovant Gene Therapies".Adis International Ltd. Springer Science+Business Media.
  7. ^"Axovant Reports Results of Exploratory Phase 2 Clinical Study of Nelotanserin in Lewy Body Dementia Patients Experiencing REM Sleep Behavior Disorder".Sio Gene Therapies. December 10, 2018. Retrieved7 May 2023.
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT3–7
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Stub icon

Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Nelotanserin&oldid=1296238626"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp